Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology.
Carolina Sgarioni Camargo VinceMaría Sol BrassescoBruna Minniti MançanoLauro Jose GregianinEdna Kakitani CarboneAdham do Amaral E CastroViviane Sayuri Yamachira DwanRoberta Zeppini Menezes da SilvaCassia Silvestre MarianoJuliana França da MataMarcelo Oliveira SilvaEliana Maria Monteiro CaranCarla Renata Pacheco Donato MacedoGildene Alves da CostaTereza Cristina EstevesLuciana Nunes SilvaSima Esther FermanFlavia Delgado MartinsLilian Maria CristófaniVicente Odone FilhoMarcelo Milone SilvaRui Manuel Vieira ReisMara Albonei Dudeque PianovskiPaulo Vidal CampregherMayara Satsuki KuniiKarla Emilia de Sá RodriguesNeviçolino Pereira Carvalho FilhoElvis Terci Valeranull nullPublished in: JCO precision oncology (2024)
This real-world study confirms favorable agnostic tumor OR rates to larotrectinib in children with NTRK-fused tumors. Better coordination to facilitate access to medication remains a challenge, particularly in middle-income countries like Brazil.